jama tirzepatide In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but offered no additional benefit over semaglutide. #ESCCongress #WCCardio 📉 Only 3% of eligible

We did a random effects meta-analysis including 590 participants assigned to GLP-1 analogues groups and 521 assigned to the sitagliptin groups

15 Unlike granulysin, the concentrations of granzyme B, perforin, and soluble Fas ligand (sFasL) in the blister fluid were insufficient to produce distinct cytotoxicity

Following several years of what many practitioners called a regulatory winter for peptide therapies, recent announcements from the Department of Health and Human Services and the Food and Drug Administration have signaled a massive shift in policy

The results are presented in tables and schemes

Patients with Parkinson's disease should not use GLP-1 receptor agonists outside of clinical trials or specific medical supervision for diabetes or obesity

CardioMAX includes 84 mg of EPA and 56 mg of DHA per chew, which helps separate it from formulas that wave vaguely at heart support without bringing omega-3s into the picture